Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation

Giampaolo Niccoli1, Cristina Spaziani, Marcello Marino

  • 1Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. gniccoli73@hotmail.it

Insights

Aspirin use before ST-elevation myocardial infarction (STEMI) significantly reduces high thrombus burden during percutaneous coronary intervention. This finding highlights aspirin

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Coronary Syndromes

Background:

  • Myocardial no-reflow can diminish the benefits of urgent coronary revascularization in ST-elevation myocardial infarction (STEMI).
  • Distal embolization, driven by high coronary thrombotic burden, is a key mechanism contributing to no-reflow.
  • Predicting and mitigating high thrombus burden is crucial for improving outcomes in STEMI patients.

Purpose of the Study:

  • To identify predictors of angiographic thrombus grade in patients undergoing primary percutaneous coronary intervention for STEMI.
  • To assess the association between pre-admission therapies and thrombus burden.
  • To inform strategies for reducing thrombotic complications during STEMI treatment.

Main Methods:

  • A prospective study of 91 patients with first STEMI undergoing primary percutaneous coronary intervention within 12 hours of symptom onset.
  • Angiographic thrombus grade assessed using the Gibson score, categorizing patients into high (HTG) or low thrombus grade (LTG) groups.
  • Multivariate analysis to determine independent predictors of HTG, examining clinical, angiographic, procedural, and laboratory data.

Main Results:

  • Patients with high thrombus grade (HTG) had a significantly higher white blood cell count (p=0.015).
  • Pre-admission aspirin and beta-blocker use was less frequent in the HTG group (p=0.01 and p=0.03, respectively).
  • Lack of previous aspirin therapy was the sole independent predictor of HTG (OR 6.14, p=0.04).

Conclusions:

  • Previous aspirin therapy is associated with a reduced angiographic thrombus grade in STEMI patients undergoing primary percutaneous coronary intervention.
  • These findings underscore the importance of aspirin use in the primary prevention of STEMI.
  • Optimizing aspirin utilization may help mitigate distal embolization and improve revascularization outcomes.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...